-
Signature
-
David Watson
-
Issuer symbol
-
APLS
-
Transactions as of
-
17 Nov 2025
-
Transactions value $
-
-$100,300
-
Form type
-
4
-
Filing time
-
18 Nov 2025, 10:05:23 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Watson David O. |
General Counsel |
C/O APELLIS PHARMACEUTICALS, INC, 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM |
David Watson |
18 Nov 2025 |
0001657719 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
APLS |
Common Stock |
Sale |
-$100K |
-5K |
-4.4% |
$20.06 |
109K |
17 Nov 2025 |
Direct |
F1 |
| holding |
APLS |
Common Stock |
|
|
|
|
|
10K |
17 Nov 2025 |
Indirect Owner (Custodial Account for minor children) |
F2 |
| holding |
APLS |
Common Stock |
|
|
|
|
|
50.1K |
17 Nov 2025 |
Indirect Owner (The David O. Watson Irrevocable Trust of 2023) |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: